VLDL receptor gene therapy for reducing atherogenic lipoproteins

Over the past 40 years, there has been considerable research into the management and treatment of atherogenic lipid disorders. Although the majority of treatments and management strategies for cardiovascular disease (CVD) center around targeting low-density lipoprotein cholesterol (LDL-C), there is...

Descripción completa

Detalles Bibliográficos
Autores principales: Krauss, Ronald M., Lu, Jonathan T., Higgins, Joseph J., Clary, Cathryn M., Tabibiazar, Ray
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950951/
https://www.ncbi.nlm.nih.gov/pubmed/36739970
http://dx.doi.org/10.1016/j.molmet.2023.101685

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9950951/
https://www.ncbi.nlm.nih.gov/pubmed/36739970
http://dx.doi.org/10.1016/j.molmet.2023.101685

Ejemplares similares